Clinical Trial Update: PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PF-06463922 in crizotinib-pretreated ROS1-positive non-small-cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PF-06463922

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN